Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UroGen submits new drug application to FDA for UGN-102
UGN-102 is currently in Phase III development for the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer. Credit: National Cancer Institute on Unsplash.
UGN-102 is currently in Phase III development for the treatment of low-grade, intermediate-risk, non-muscle invasive bladder cancer. Credit: National Cancer Institute on Unsplash.